Biotech week ahead, April 6

Biotech stocks went along with the broader market flow in the week ended April 3, with the COVID-19 pandemic dictating sentiment. The week witnessed a host of clinical readouts and pre-announcements in light of the COVID-19 impact.
The stock that made headlines during the week was Amarin Corporation plc AMRN 8.43%, which slumped on an adverse court ruling.
The following are catalysts that could impact biotech stocks in the unfolding week.
The focus is likely to stay on pre-clinical and clinical updates from companies developing therapies and/or vaccines for SARS-CoV-2. More companies are expected to update investors with preliminary first-quarter results that factor in the COVID-19 impact.
Conferences

• Goldman Sachs Cell Therapy Day: April 6
• 2020 Wells Fargo Biotech Virtual Corporate Access Day: April 7 in Boston, Massachusetts
• Canaccord Genuity Horizons in Oncology Virtual Event: April 8 in Boston
• 2020 Wells Fargo Biotech Virtual Corporate Access Day: April 9 in San Francisco, California

Clinical Readouts

Menlo Therapeutics Inc MNLO 1.89%: top-line data from two ongoing serlopitant Phase 3 studies in pruritus associated with prurigo nodularis (late March/early April)
Oragenics Inc OGEN 2.11%: Results from the Phase 2 study of AG013 in oral mucositis (early 2020)

Earnings

• AngioDynamics, Inc. ANGO 2.03% (Tuesday after the close)
• PAVmed Inc PAVM 5.21% (Thursday after the close)

IPOs

Keros Therapeutics, which develops therapies for hematological and neuromuscular disorders, plans to offer 5 million shares in an IPO priced between $14 and $16. The company has applied to list its shares on the Nasdaq under the ticker symbol “KROS.”

IPO Quiet Period Expiry

Imara Inc IMRA
https://www.benzinga.com/general/biotech/20/04/15729886/the-week-ahead-in-biotech-spotlight-on-q1-pre-announcements-as-covid-19-continues-to-disrupt-oper